MEDICAL PRIVACY LAWS SHOULD NOT REQUIRE PATIENT CONSENT FOR POST-MARKETING REGISTRIES -- PhRMA; LIMITS ON RIGHTS TO RECORDS IN CLINICALS SUGGESTED
Medical privacy legislation should not require sponsors to obtain patient consent for post-marketing registries when subjects are not identifiable, Glaxo Wellcome VP-Worldwide Clinical Research Richard Kent maintained at a Feb. 4 HHS hearing on medical privacy. Kent cited as an example Glaxo Wellcome's registry for the anti-convulsant Lamictal, which was established to determine whether the drug is teratogenic in humans.
You may also be interested in...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth